GINA CUNEO-RAMOS: Open Payments
NPI 1477970663 · NEW YORK, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,421 in 127 payments from 23 companies in 2025. Trend: 2023 $3,568 · 2024 $3,423 · 2025 $3,421
Food & beverage: $3,421
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 29 | $642 |
| AstraZeneca Pharmaceuticals LP | 20 | $507 |
| Novo Nordisk Inc | 6 | $420 |
| Otsuka America Pharmaceutical, Inc. | 11 | $239 |
| Medtronic, Inc. | 5 | $212 |
| Lilly USA, LLC | 9 | $195 |
| Abbott Laboratories | 2 | $155 |
| Vanda Pharmaceuticals Inc. | 8 | $146 |
| Exact Sciences Corporation | 4 | $122 |
| PFIZER INC. | 5 | $98 |
Products named: VRAYLAR, REXULTI, BREZTRI, Ozempic, MINIMED 780G, FARXIGA, FREESTYLE LIBRE, FANAPT.
Industry payments across NY — which companies pay providers there.
